Obiettivo
- To understand the genetic and molecular bases of the variable phenotypic expression of major hemoglobinopathies and in particular sickle cell disease (SCD);
- To rationalise the therapeutic induction of foetal haemoglobin (HbF) in hemoglobinopathies by pharmacological means.
- In the social context of Benin, an affected new-born with SCD is rarely retrieved for regular clinical follow-up. We circumvented this difficulty by focusing our attention on identifying pregnancies' at-risk for giving birth to a child with SCD and by providing information and counselling. A total of 2300 pregnancies was followed : 5% of the pregnancies with SCD were managed clinically. 1028 new-borns were available for neonatal screening and 12% had SCD with 64% traits. 91 new-borns entered the clinical surveillance programme (75% compliance of the parents) which included prophylaxis against infections. Among them 25% had an associated G6PDH deficiency (G6PDA-). The outcome of these studies will be assessed only in year/3.
- Contribution to the culture of continuous learning : participation to the first regional specialised course of haematology on SCD held at Cotonou BENIN (12-16 Dec. 1995) with the aim of disseminating the state of the art of biological and clinical aspects of SCD to trainees from 11 different African countries. A "SCD network" among these countries has been created. The prevalence of G6PD deficiency by "spot test" in Mauritius is 5.5% (school and blood donor screening n = 1435). Molecular analysis (PCR RFLP, SSCP, Nucleotide sequencing) confirmed the phenotype data but also revealed the nature of mutant alleles (G6PD Orissa, Kerala Kalyan, Med-Union, Hammersmith, A-) consistent with the ancestral population input. 16 G6PD novel variants await characterisation. We could not observe SCD in association with G6PD deficiency in this population. More SCD cases need to be screened. Transfer of knowledge and know how was extremely efficient and a specialised centre for hemoglobinopathies was set up and now functions autonomously. Extensive comparison of regulatory region polymorphisms of the á-locus in Indian and different African sickle cell traits (taking into account the a globin gene status) revealed that the sickle cell gene from India has intrinsic thalassemic characteristics with resulting reduced expression of HbS and thus might contribute along with elevated HbF expression to the attenuated form of the disease in India as compared to severe form in Africa. A large three generation family consisting of 60 members with 16 presenting a á-globin gene cluster dependent HPFH (moderate increase in HbF in the basal state with further increase in response to anaemic stress) from Algeria is presently under investigation for defining the molecular basis of such forms of HPFH. Clinical trial of hydroxyurea (HU) treatment for the past 2 years of the first generation African SCD children followed at Paris (4 boys and 3 girls, age range 4-16 years) revealed :
- an excellent compliance;
- all were "responders" in terms of increase in HbF;
- SCD with "Senegal" haplotype had higher increment in HbF than others;
- absence of HU dose - dependence in HbF increase;
- beneficial affect of HU (in terms of hospitalisation for vaso occlusive crisis or acute thoracic syndrome/patienVyear is not limited to increment to HbF alone;
- HU caused reduction in serum iron, supplementation of which, further increased the HbF level all leading to the conclusion that UH treatment appears as an efficient cost-effective alternative for situations where exchange transfusion was the role (excepting strokes) and thus avoiding transfusion-associated risks.
- To appreciate :
- the feasibility of a comprehensive program on SCD based upon neonatal screening, parental education and early medical follow-up in an African setting;
- the impact of this program on the related morbidity and mortality (natural history).
- Epidemiology of G6PD deficiency and its interaction with SCD;
- Comparison of severe form of African sticklers with mild ones from India to assess the prognostic value of associated genetic modifiers (genetic polymorphism of the critical regulatory DNA elements of the alpha-globin gene cluster, alpha-globin gene status, genetic propensity to express HbF;
- Hydroxyurea treatment in paediatric SCD patients and follow up;
- Recruitment of families for studying genetic modifiers (unlinked to the alpha-globin gene cluster), involved in the genetic control of HbF expression (F-cell genetics).
Campo scientifico (EuroSciVoc)
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.
CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP. Cfr.: Il Vocabolario Scientifico Europeo.
- scienze mediche e della salute scienze della salute salute pubblica epidemiologia
- scienze mediche e della salute medicina clinica ostetricia
- scienze mediche e della salute medicina clinica ematologia
- scienze mediche e della salute medicina di base neurologia ictus
- scienze naturali scienze biologiche genetica nucleotidi
È necessario effettuare l’accesso o registrarsi per utilizzare questa funzione
Programma(i)
Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.
Programmi di finanziamento pluriennali che definiscono le priorità dell’UE in materia di ricerca e innovazione.
Argomento(i)
Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.
Dati non disponibili
Gli inviti a presentare proposte sono suddivisi per argomenti. Un argomento definisce un’area o un tema specifico per il quale i candidati possono presentare proposte. La descrizione di un argomento comprende il suo ambito specifico e l’impatto previsto del progetto finanziato.
Invito a presentare proposte
Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.
Dati non disponibili
Procedura per invitare i candidati a presentare proposte di progetti, con l’obiettivo di ricevere finanziamenti dall’UE.
Meccanismo di finanziamento
Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.
Meccanismo di finanziamento (o «Tipo di azione») all’interno di un programma con caratteristiche comuni. Specifica: l’ambito di ciò che viene finanziato; il tasso di rimborso; i criteri di valutazione specifici per qualificarsi per il finanziamento; l’uso di forme semplificate di costi come gli importi forfettari.
Coordinatore
75019 Paris
Francia
I costi totali sostenuti dall’organizzazione per partecipare al progetto, compresi i costi diretti e indiretti. Questo importo è un sottoinsieme del bilancio complessivo del progetto.